![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Exelixis Files IND Application for Novel Anticancer Compound XL820
Exelixis Files IND Application for Novel Anticancer Compound XL820
Exelixis has submitted an investigational new drug application (IND) to the FDA for XL820.
This novel small molecule anticancer compound potently inhibits receptor tyrosine kinases implicated in tumor proliferation and vascularization. XL820 is the fifth compound to advance in clinical development from Exelixis' internal drug discovery capabilities.
Pending clearance by the FDA, Exelixis intends to initiate a Phase I clinical trial for XL820.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct